These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 16533763

  • 1. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
    Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC.
    Clin Cancer Res; 2006 Mar 01; 12(5):1412-9. PubMed ID: 16533763
    [Abstract] [Full Text] [Related]

  • 2. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
    Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM, Xie Y.
    J Clin Pathol; 2006 Sep 01; 59(9):947-51. PubMed ID: 16489177
    [Abstract] [Full Text] [Related]

  • 3. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells.
    Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ.
    Oncogene; 2003 Jun 19; 22(25):3943-51. PubMed ID: 12813468
    [Abstract] [Full Text] [Related]

  • 4. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, Terashima M, Fujime M, Igawa M, Dahiya R.
    Clin Cancer Res; 2005 Feb 01; 11(3):1028-36. PubMed ID: 15709168
    [Abstract] [Full Text] [Related]

  • 5. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, Singal R.
    Mol Cancer; 2006 Jul 18; 5():28. PubMed ID: 16848908
    [Abstract] [Full Text] [Related]

  • 6. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R, Costa VL, Cerveira N, Carvalho AL, Hoque MO, Ribeiro FR, Oliveira J, Teixeira MR, Sidransky D, Jerónimo C.
    J Mol Med (Berl); 2006 Nov 18; 84(11):911-8. PubMed ID: 17016690
    [Abstract] [Full Text] [Related]

  • 7. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas.
    Chi SG, deVere White RW, Muenzer JT, Gumerlock PH.
    Clin Cancer Res; 1997 Oct 18; 3(10):1889-97. PubMed ID: 9815578
    [Abstract] [Full Text] [Related]

  • 8. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
    Wong CM, Lee JM, Ching YP, Jin DY, Ng IO.
    Cancer Res; 2003 Nov 15; 63(22):7646-51. PubMed ID: 14633684
    [Abstract] [Full Text] [Related]

  • 9. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W, Wang L, Ma Q, Qi M, Lu N, Zhang L, Han B.
    Prostate; 2015 Aug 01; 75(11):1197-205. PubMed ID: 25877612
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.
    Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH.
    Oncogene; 2004 Feb 19; 23(7):1405-11. PubMed ID: 14661059
    [Abstract] [Full Text] [Related]

  • 12. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.
    Yuan BZ, Durkin ME, Popescu NC.
    Cancer Genet Cytogenet; 2003 Jan 15; 140(2):113-7. PubMed ID: 12645648
    [Abstract] [Full Text] [Related]

  • 13. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
    Enokida H, Shiina H, Igawa M, Ogishima T, Kawakami T, Bassett WW, Anast JW, Li LC, Urakami S, Terashima M, Verma M, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R.
    Cancer Res; 2004 Sep 01; 64(17):5956-62. PubMed ID: 15342374
    [Abstract] [Full Text] [Related]

  • 14. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
    Shiina H, Breault JE, Basset WW, Enokida H, Urakami S, Li LC, Okino ST, Deguchi M, Kaneuchi M, Terashima M, Yoneda T, Shigeno K, Carroll PR, Igawa M, Dahiya R.
    Cancer Res; 2005 Mar 15; 65(6):2130-8. PubMed ID: 15781623
    [Abstract] [Full Text] [Related]

  • 15. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
    Liu W, Gong J, Hu J, Hu T, Sun Y, Du J, Sun C, Guan M, Jiang H, Lu Y.
    Urology; 2011 Apr 15; 77(4):1006.e1-7. PubMed ID: 21310466
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A quantitative promoter methylation profile of prostate cancer.
    Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D.
    Clin Cancer Res; 2004 Dec 15; 10(24):8472-8. PubMed ID: 15623627
    [Abstract] [Full Text] [Related]

  • 18. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features.
    Guan M, Xu C, Zhang F, Ye C.
    Int J Cancer; 2009 Jan 01; 124(1):88-94. PubMed ID: 18821581
    [Abstract] [Full Text] [Related]

  • 19. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
    Sørensen KD, Borre M, Ørntoft TF, Dyrskjøt L, Tørring N.
    Int J Cancer; 2008 Feb 01; 122(3):509-19. PubMed ID: 17943724
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of EphA5 by promoter methylation in human prostate cancer.
    Li S, Zhu Y, Ma C, Qiu Z, Zhang X, Kang Z, Wu Z, Wang H, Xu X, Zhang H, Ren G, Tang J, Li X, Guan M.
    BMC Cancer; 2015 Jan 22; 15():18. PubMed ID: 25609195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.